Ibandronate in malignant bone diseases and osteoporosis – preclinical results

Oncology Research and Treatment

Volumn 20, Issue 3, 1997, Pages 204-208

  Bauss, F ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Bisphosphonates; Bone metastases; Hypercalcemia of malignancy; Ibandronate; Osteoporosis; Tumor osteolysis

Indexed keywords

IBANDRONIC ACID;

BONE CANCER; BONE MINERALIZATION; BONE STRENGTH; DRUG EFFICACY; HUMAN; HYPERCALCEMIA; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0030802839     PISSN: 22965270     EISSN: None     Source Type: Journal    
DOI: 10.1159/000218939     Document Type: Article

References (31)

1. Fleisch H: Bisphosphonates: Pharmacology and use in the treatment of tumour-induced hypercalceamia and metastatic bone disease. Drugs 1991:42:919-944.
2. Jung A, Bisaz S, Fleisch H: The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif Tissue Int 1973:11269-280.
3. Shinoda H, Adamek G, Felix R, Fleisch H, Schenk R, Flagan P: Structure-activity relationships of various bisphosphonates Calcif Tissue Int 1983:35:87-99.
4. Sahni M, Giinther H, Fleisch H, Collin P, Martin TJ: Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 1993:91: 2004-2011.
5. Vittd C, Fleisch H, Guenther H: Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 1996:137: 2324-2333.
6. Rodan GA, Fleisch II: Bisphosphonates: Mechanisms of action. J Clin Invest 1996;97:2692-2696.
7. Fleisch H: Bisphosphonates in bone disease: From the laboratory to the patient. 3rd edition. New York. Parthenon Publishing Group. 1997.
8. Bauss F, Miihlbauer RC: BM 21.0955. monosodium salt, monohydrate. Drugs Fut 1994:19:13-16.
9. Mühlbauer RC, Bauss F, Schenk R, Janner M, Bosies E, Strein K, Fleisch H: BM 21.0955. a potent new bisphosphonale to inhibit bone resorption. J Bone Miner Res 1991:6:1003-1011.
10. Miihlbauer RC: Biochemical assessment of bone metabolism in rodents: in Ziegler R. Pfeilschifter J. Bräutigam M (eds): Sex steroids and bone. Berlin. Springer, 1993:191-202.
11. Serdar-Obermeier M, Bauss F: Effects of the bisphosphonale BM 21.0955 on hypercalcemia and hypercalciuria induced by the Walker carcinosarcoma 256 in TPTX rats. Calcif Tissue Int 1993:52: (suppl): S70. No. 279.
12. Rizzoli R, Caverzasio J, Bauss F, Bonjour J-P: Inhibition of bone resorption by the bisphosphonale BM 21.0955 is not associated with an alteration of the renal handling of calcium in rats infused with parathyroid hormone related protein. Bone 1992:13: 321-325.
13. Williams P, Mbalaviele G, Sasaki A, Dunstan C, Adams R, Bauss F, Mundy GR, Yoncda T: Multi-step inhibition of breast cancer metastasis to bone. J Bone Miner Res 1995;10(suppl 1): S169. No. 121.
14. Pluijm G van der, Vloedgraven H, Beek E van, Wee-Pals L van der, Löwik C: Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996:98:698-705.
15. Monier-Faugere M-C, Friedler RM, Bauss F, Malluche FIH: A new bisphosphonale. BM 21.0955. prevents bone loss associated with cessation of ovarian function in experimental dogs J Bone Miner Res 1993:8:1345-1355.
16. Gcng Z, Faugere M-C, Qi O, Bauss F, Malluche HH: Ibandronate reverses bone loss after cessation of ovarian function in beagle dogs J Bone Miner Res 1995;10(suppl 1): S199, No. P238.
17. Bauss F, Kling L, Sponcr G: Effects of continuous and cyclical administration of ibandronate on bone mass in ovariectomized (ovx) aged rats Bone 1995:17:597 No. 2.
18. Rahn BA, Wahl D, Bess S, Lalla S, Vogl H, Cordey J, Bauss F: Effccls of dose and adminislralion patlern of ibandronale on mechanical properties of femurs of ovarieclomized rals. Bone 1995;17:604 No. 26.
19. Schenk R, Merz WA, Mühlbauer R, Russel RGG, Fleisch H: Effect of ethane-l-hydroxy-l.l-diphos-phonale (F.HDP) and dichloromethylene diphospho-nale (CL2MDP) on Ihe calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif Tissue Ini 1973:11: 196-214.
20. Schenk R, Eggli P, Fleisch IT, Rosini S: Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int 1986;38:342-349.
21. Gasser AB, Morgan DB, Fleisch H. Richellc LJ: The influence of two diphosphonates on calcium metabolism in the rat. Clin Sei 1972:43:31-45.
22. 45Ca kinetics in the intact rat. Osteoporosis Int 1996:6:166-170.
23. Muhlbaucr RC, Fleisch H: A method for continual monitoring of bone resorption in the rat: Evidence for a diurnal rhythm. Amcr J Physiol 1990:259: R679-R689.
24. Bauss F, Schenk R, Mullcr-Beckmann B, Sponcr G: Some aspects on bone quality following long-term treatment with ibandronate in adult beagle dogs Bone 1995:17:598, No. 3.
25. Affentranger U. Bauss F. Qin L. Cordey J. MclffRahn BA: Mechanical properties of cancellous and cortical bone after long term ibandronate dosing in beagle dogs. Bone 1995:17:604, No. 25.
26. Lalla S, Hothorn L, Ochlich PP, Bader R, Bauss F: The effects of 2-year treatment with high doses of ibandronate on mechanical properties and bone mineral density of rat vertebrae. J Bone Miner Res 1996:11 (suppl 1): S336. No. M116.
27. Pechersdorfer M, Ludwig H, Schlosser K, Buck S, Huss H-J, Body J-J: Administration of the bisphos-phonate ibandronate (BM 21.0955) by intravenous bolus injection. J Bone Miner Res 1996:11:587-593.
28. Ralston SH, Thiébaud D, Herrmann Z, Steinhauer EU, Thtirlimann B, Walls J, Lichinitser MR, Rizzoli R, Hagbcrg H, Huss H-J, Tubiana-Hulin M, Body J-J: Dose-response study of ibandronate in the treatment of cancer-associated hypercalcemia. Br J Cancer 1997;75:295-300.
29. Thiébaud D, Kriegbaum H, Huss H, Christiansen C, Burckhardt P: Intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis; in Papapoulos SE. Lips P. Pols HAP, Johnston CC. Delmas PD (eds): Osteoporosis 1996. Amsterdam. Elsevier 1996:321-325.
30. Ravn P, Clemmescn B, Riis BJ, Christiansen C: The effect on bone mass and markers of different doses of ibandronate: A new bisphosphonale for prevention and treatment of postmenopausal osteoporosis: A i-year. randomized, double-blind, piacebo-con-trolled dose-finding study. Bone 1996:19:527-533.
31. Grauer A, Heichel S, Knaus J, Ziegler R: Longterm effects of ibandronate in Paget's disease of bone. J Bone Miner Res 1996:11 (suppl 1): S498.